HSDT Fundamental Analysis - SOLANA CO

Name: SOLANA CO (HSDT) Stock
Brand: SOLANA CO
Rating: 2.5 (3 reviews)

Fundamental Rating

Taking everything into account, HSDT scores 3 out of 10 in our fundamental rating. HSDT was compared to 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for HSDT as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, HSDT is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HSDT has reported negative net income.

In the past year HSDT has reported a negative cash flow from operations.

In the past 5 years HSDT always reported negative net income.

In the past 5 years HSDT always reported negative operating cash flow.

1.2 Ratios

HSDT has a Return On Assets of -269.67%. This is amonst the worse of the industry: HSDT underperforms 95.24% of its industry peers.

With a Return On Equity value of -353.22%, HSDT is not doing good in the industry: 77.78% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-269.67%
ROE	-353.22%
ROIC	N/A

ROA(3y)-175.99%

ROA(5y)-174.45%

ROE(3y)-552.67%

ROE(5y)-436.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

HSDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HSDT does not have a ROIC to compare to the WACC, probably because it is not profitable.

HSDT has more shares outstanding than it did 1 year ago.

HSDT has more shares outstanding than it did 5 years ago.

HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 38.93 indicates that HSDT is not in any danger for bankruptcy at the moment.

HSDT has a better Altman-Z score (38.93) than 98.41% of its industry peers.

There is no outstanding debt for HSDT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	38.93

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

HSDT has a Current Ratio of 4.32. This indicates that HSDT is financially healthy and has no problem in meeting its short term obligations.

HSDT's Current ratio of 4.32 is fine compared to the rest of the industry. HSDT outperforms 73.02% of its industry peers.

A Quick Ratio of 3.69 indicates that HSDT has no problem at all paying its short term obligations.

HSDT's Quick ratio of 3.69 is fine compared to the rest of the industry. HSDT outperforms 72.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.32
Quick Ratio	3.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HSDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -212.36%.

The Revenue for HSDT has decreased by -50.34% in the past year. This is quite bad

HSDT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.09% yearly.

EPS 1Y (TTM)-212.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%83.39%

Revenue 1Y (TTM)-50.34%

Revenue growth 3Y0%

Revenue growth 5Y-19.09%

Sales Q2Q%-76.37%

3.2 Future

Based on estimates for the next years, HSDT will show a very strong growth in Earnings Per Share. The EPS will grow by 40.27% on average per year.

The Revenue is expected to grow by 177.16% on average over the next years. This is a very strong growth

EPS Next Y87.29%

EPS Next 2Y40.27%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-20.09%

Revenue Next 2Y18.3%

Revenue Next 3Y346.25%

Revenue Next 5Y177.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSDT. In the last year negative earnings were reported.

Also next year HSDT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

HSDT's earnings are expected to grow with 40.27% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.27%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HSDT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SOLANA CO

NASDAQ:HSDT (10/31/2025, 8:00:01 PM)

Premarket: 5.875 -0.07 (-1.09%)

5.94

-0.04 (-0.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-10 2025-11-10/amc

Inst Owners1.11%

Inst Owner Change0.04%

Ins Owners0%

Ins Owner Change0%

Market Cap239.38M

Revenue(TTM)295.00K

Net Income(TTM)-21285000

Analysts43.33

Price TargetN/A

Short Float %2.48%

Short Ratio0.65

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)26.48%

Min EPS beat(2)13.79%

Max EPS beat(2)39.17%

EPS beat(4)3

Avg EPS beat(4)13.75%

Min EPS beat(4)-6.38%

Max EPS beat(4)39.17%

EPS beat(8)6

Avg EPS beat(8)15.45%

EPS beat(12)9

Avg EPS beat(12)20.9%

EPS beat(16)12

Avg EPS beat(16)16.5%

Revenue beat(2)0

Avg Revenue beat(2)-47.88%

Min Revenue beat(2)-51.96%

Max Revenue beat(2)-43.79%

Revenue beat(4)1

Avg Revenue beat(4)-28.35%

Min Revenue beat(4)-66.67%

Max Revenue beat(4)49.02%

Revenue beat(8)3

Avg Revenue beat(8)-24.88%

Revenue beat(12)6

Avg Revenue beat(12)-16.96%

Revenue beat(16)9

Avg Revenue beat(16)-4.5%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	811.46
P/FCF	N/A
P/OCF	N/A
P/B	39.72
P/tB	39.72
EV/EBITDA	N/A

EPS(TTM)-1969.73

EYN/A

EPS(NY)-65.79

Fwd EYN/A

FCF(TTM)-0.28

FCFYN/A

OCF(TTM)-0.28

OCFYN/A

SpS0.01

BVpS0.15

TBVpS0.15

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-269.67%
ROE	-353.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-175.99%

ROA(5y)-174.45%

ROE(3y)-552.67%

ROE(5y)-436.83%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	0%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.32
Quick Ratio	3.69
Altman-Z	38.93

F-Score3

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)10.97%

Cap/Depr(5y)13.37%

Cap/Sales(3y)2.54%

Cap/Sales(5y)5.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-212.36%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%83.39%

EPS Next Y87.29%

EPS Next 2Y40.27%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-50.34%

Revenue growth 3Y0%

Revenue growth 5Y-19.09%

Sales Q2Q%-76.37%

Revenue Next Year-20.09%

Revenue Next 2Y18.3%

Revenue Next 3Y346.25%

Revenue Next 5Y177.16%

EBIT growth 1Y-21.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-5.75%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-6%

OCF growth 3YN/A

OCF growth 5YN/A

SOLANA CO / HSDT FAQ

What is the fundamental rating for HSDT stock?

ChartMill assigns a fundamental rating of 3 / 10 to HSDT.

Can you provide the valuation status for SOLANA CO?

ChartMill assigns a valuation rating of 1 / 10 to SOLANA CO (HSDT). This can be considered as Overvalued.

How profitable is SOLANA CO (HSDT) stock?

SOLANA CO (HSDT) has a profitability rating of 0 / 10.

Can you provide the financial health for HSDT stock?

The financial health rating of SOLANA CO (HSDT) is 8 / 10.

SOLANA CO (HSDT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SOLANA CO / HSDT FAQ

What is the fundamental rating for HSDT stock?

Can you provide the valuation status for SOLANA CO?

How profitable is SOLANA CO (HSDT) stock?

Can you provide the financial health for HSDT stock?